Cargando…
Comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma
OBJECTIVES: To assess if excess absolute risk (EAR) of radiation-induced solid cancer can be used to rank radiotherapy plans for treatment of Hodgkin lymphoma (HL) in a statistically significant way. METHODS: EAR models, calibrated with data from the Life Span Study and HL survivors, have been incor...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Institute of Radiology.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506169/ https://www.ncbi.nlm.nih.gov/pubmed/33237825 http://dx.doi.org/10.1259/bjr.20200354 |
_version_ | 1784581685968371712 |
---|---|
author | Timlin, Claire Loken, James Kruse, Jon Miller, Robert Schneider, Uwe |
author_facet | Timlin, Claire Loken, James Kruse, Jon Miller, Robert Schneider, Uwe |
author_sort | Timlin, Claire |
collection | PubMed |
description | OBJECTIVES: To assess if excess absolute risk (EAR) of radiation-induced solid cancer can be used to rank radiotherapy plans for treatment of Hodgkin lymphoma (HL) in a statistically significant way. METHODS: EAR models, calibrated with data from the Life Span Study and HL survivors, have been incorporated into a voxelised risk-calculation software, which is used to compare four treatment modalities planned for five virtual HL patients. Organ-specific parameters are generated repeatedly in a Monte Carlo fashion to model their uncertainties. This in turn enables a quantitative estimation of the EAR uncertainties. RESULTS: Parameter-driven uncertainties on total EAR are around 13%, decreasing to around 2–5% for relative EAR comparisons. Total EAR estimations indicate that intensity modulated proton therapy decreases the average risk by 40% compared to the intensity modulated radiation therapy plan, 28% compared to the volumetric modulated arc therapy plan whereas the three-dimensional conformal radiation therapy plan is equivalent within the uncertainty. CONCLUSION: Relative EAR is a useful metric for distinguishing between radiotherapy plans in terms of second cancer risk. ADVANCES IN KNOWLEDGE: Relative EAR is not dominated by model or parameter uncertainties and can be used to guide the choice of radiotherapy for HL patients. |
format | Online Article Text |
id | pubmed-8506169 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The British Institute of Radiology. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85061692021-10-29 Comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma Timlin, Claire Loken, James Kruse, Jon Miller, Robert Schneider, Uwe Br J Radiol Full Paper OBJECTIVES: To assess if excess absolute risk (EAR) of radiation-induced solid cancer can be used to rank radiotherapy plans for treatment of Hodgkin lymphoma (HL) in a statistically significant way. METHODS: EAR models, calibrated with data from the Life Span Study and HL survivors, have been incorporated into a voxelised risk-calculation software, which is used to compare four treatment modalities planned for five virtual HL patients. Organ-specific parameters are generated repeatedly in a Monte Carlo fashion to model their uncertainties. This in turn enables a quantitative estimation of the EAR uncertainties. RESULTS: Parameter-driven uncertainties on total EAR are around 13%, decreasing to around 2–5% for relative EAR comparisons. Total EAR estimations indicate that intensity modulated proton therapy decreases the average risk by 40% compared to the intensity modulated radiation therapy plan, 28% compared to the volumetric modulated arc therapy plan whereas the three-dimensional conformal radiation therapy plan is equivalent within the uncertainty. CONCLUSION: Relative EAR is a useful metric for distinguishing between radiotherapy plans in terms of second cancer risk. ADVANCES IN KNOWLEDGE: Relative EAR is not dominated by model or parameter uncertainties and can be used to guide the choice of radiotherapy for HL patients. The British Institute of Radiology. 2021-05-01 2021-04-09 /pmc/articles/PMC8506169/ /pubmed/33237825 http://dx.doi.org/10.1259/bjr.20200354 Text en © 2021 The Authors. Published by the British Institute of Radiology https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 Unported License http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Full Paper Timlin, Claire Loken, James Kruse, Jon Miller, Robert Schneider, Uwe Comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma |
title | Comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma |
title_full | Comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma |
title_fullStr | Comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma |
title_full_unstemmed | Comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma |
title_short | Comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma |
title_sort | comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma |
topic | Full Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506169/ https://www.ncbi.nlm.nih.gov/pubmed/33237825 http://dx.doi.org/10.1259/bjr.20200354 |
work_keys_str_mv | AT timlinclaire comparingsecondcancerriskformultipleradiotherapymodalitiesinsurvivorsofhodgkinlymphoma AT lokenjames comparingsecondcancerriskformultipleradiotherapymodalitiesinsurvivorsofhodgkinlymphoma AT krusejon comparingsecondcancerriskformultipleradiotherapymodalitiesinsurvivorsofhodgkinlymphoma AT millerrobert comparingsecondcancerriskformultipleradiotherapymodalitiesinsurvivorsofhodgkinlymphoma AT schneideruwe comparingsecondcancerriskformultipleradiotherapymodalitiesinsurvivorsofhodgkinlymphoma |